We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using Multi-exponential T2 Components

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2014 by AHS Cancer Control Alberta.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00813787
First Posted: December 23, 2008
Last Update Posted: October 3, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AHS Cancer Control Alberta
December 19, 2008
December 23, 2008
October 3, 2014
February 2009
April 2015   (Final data collection date for primary outcome measure)
T2 characteristics of glioma tissue versus normal [ Time Frame: Before radiotherapy treatment begins ]
T2 characteristics of glimoa tissue versus normal [ Time Frame: Before radiotherapy treatment begins ]
Complete list of historical versions of study NCT00813787 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using Multi-exponential T2 Components
Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using a Specialized MRI Technique Called Multiexponential T2 Component Analysis
The purpose of this study is to see if a specialized imaging technique using MRI called multi-exponential T2 component analysis can reliably differentiate between normal brain and brain tumour.
Existing methods of contouring tumours for radiation therapy involve manual interpretations of qualitative diagnostic images. These methods, being qualitative, do not offer a consistent and reproducible platform for contouring, making it difficult to evaluate the effects of contouring choices on treatment outcome. T2 component analysis in MRI has the potential to offer a quantitive basis for identifying tumor tissue- this potential is investigated in this pilot study.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

A. Any glioma patient who recieves treatment at our clinic (Cross Cancer Institute) who agrees to take part in the study.

B. Any normal volunteer who agrees to take part in the study.

Glioma
Not Provided
  • A. glioma
    A. glioma population
  • B. Normal brain
    B. Normal brain
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
20
April 2015
April 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Eighteen years of age or older
  • Clinical subjects must have not yet begun radiation therapy
  • Must have signed our study-specific consent form

Exclusion Criteria:

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT00813787
CNS-24534
Yes
Not Provided
Not Provided
AHS Cancer Control Alberta
AHS Cancer Control Alberta
Not Provided
Study Chair: Keith Wachowicz, PhD AHS Cancer Control Alberta
AHS Cancer Control Alberta
October 2014